Oncology

Latest News

Tech Updates: McKesson Launches Precision Oncology Consortium; Financing for RISA Labs PA Platform

By Mary Caffrey

April 17th 2025

These advances are designed to improve uptake of biomarker-driven cancer care and reduce treatment delays.

Making Novel Cancer Therapies Available Requires Choices Because Resources Are Limited

By Kyle Munz

April 14th 2025

Businessman shows medical network wooden block for health, medicine, insurance, healthcare, care, concept. Medical technology services to solve public - ภัทรชัย รัตนชัยวงค์ - stock.adobe.com.jpeg

NCCN Data Find Racial, Socioeconomic Disparities in Quality of Care for Metastatic Pancreatic Cancer

By Giuliana Grossi

April 9th 2025

Comparing Breast Cancer Treatment Outcomes Between Fee-for-Service and Medicare Advantage

By Galen Shearn-Nance, BS
Rishi R. Sachdev, BS

April 4th 2025

Woman with keloid on shoulder | Image credit: weerajata – stock.adobe.com

Deep Learning Tool Differentiates Keloids From Malignant Lesions Without Dermoscopy

By Hayden E. Klein

April 2nd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

July 17th 2017

Researchers Use STING Agonists to Reverse Resistance to Rituximab in Lymphoma Patients

Christina Mattina

According to a recent study, adding a stimulator of interferon genes (STING) agonist to rituximab for lymphoma can help provoke an immune response to the monoclonal antibody in patients who had shown resistance.

July 17th 2017

Patient Selection Vital in Ensuring Improved Response to PD-1, PD-L1 Inhibitors in NSCLC

Surabhi Dangi-Garimella, PhD

In a discussion on state-of-the-art uses for immunotherapy in the management of non—small cell lung cancer (NSCLC) at the American Society of Clinical Oncology Annual Meeting, oncologists shared their experiences with managing toxicities from immunotherapy and discussed the role of immunotherapy in specific patient populations.

July 17th 2017

An Early Stage Safety, Efficacy Study for Atezolizumab Plus Daratumumab in Advanced NSCLC

Surabhi Dangi-Garimella, PhD

An early stage international clinical trial is actively enrolling patients with relapsed, advanced or metastatic non—small cell lung cancer (NSCLC) to evaluate response to a combination of atezolizumab and daratumumab, according to a study at the 2017 Annual Meeting of the American Society of Clinical Oncology that detailed the trial design.

July 17th 2017

CMS Proposes Payment Rate Change for 340B Program

Laura Joszt, MA

Proposed change to the payment rate under the 340B program for certain Medicare Part B drugs would cut reimbursement rate in attempt to address rising drug costs.

July 17th 2017

FDA Considers Label Changes for Some Immunotherapies Due to Potential Vision Loss

Alison Rodriguez

The FDA is considering adding the risk of ocular inflammatory conditions to labels for 3 immune checkpoint inhibitors due to sight-threatening complications.

July 17th 2017

Daratumumab-Based Combination Effective in Relapsed/Refractory Multiple Myeloma, Short PFS in Heavily Pretreated Patients

Surabhi Dangi-Garimella, PhD

Managing heavily pretreated, often less fit, patients with relapsed/refractory multiple myeloma is a challenge in routine practice, as illustrated by the fact progression-free survival remains short, although daratumumab-based combination therapies are proven effective, according to results presented during a poster session at the 2017 American Society of Clinical Oncology Annual Meeting.

July 17th 2017

Phase 1 Study Results at ASCO Support First-Line Use of Daratumumab in Multiple Myeloma

Surabhi Dangi-Garimella, PhD

A phase 1 study, presented at the 2017 Annual Meeting of the American Society of Clinical Oncology, found that using daratumumab, an antibody that binds and inhibits the CD38 receptor, can improve patient response to treatment.

July 17th 2017

Daratumumab With Standard Regimen Improves PFS, ORR Independent of Cytogenetic Risk in Multiple Myeloma

Surabhi Dangi-Garimella, PhD

Updated trial results at the 2017 Annual Meeting of the American Society of Clinical Oncology showed the combinations of daratumumab with either lenalidomide and dexamethasone or bortezomib and dexamethasone prolonged progression-free survival for patients with relapsed refractory multiple myeloma.

July 15th 2017

New Blood Biomarker Offers Earlier Detection of Pancreatic Cancer

Alison Rodriguez

A new blood biomarker demonstrates its ability to detect pancreatic cancer earlier, which can lead to better treatment and outcomes, according to a study published in Science Translational Medicine.

July 14th 2017

Investor Reactions to Orphan Drug Designation Strongest for Oncology Therapies, Study Finds

Alison Rodriguez

A new study examines the impact that a pharmaceutical’s designation as an orphan drug can have on its manufacturer’s stock prices, and finds that the largest returns were for oncology drugs.

July 13th 2017

FDA Advisory Committee Confirms Support for Biosimilars to Trastuzumab, Bevacizumab

Surabhi Dangi-Garimella, PhD

The comittee voted 17-0 in favor of the Amgen/Allergan bevacizumab biosimilar candidate, ABP 215, and 16-0 in favor of Mylan’s trastuzumab biosimilar candidate, MYL-1401O.

July 13th 2017

Rose Gerber's Outlook on the Evolution and Goals of COA'S CPAN

The Community Oncology Alliance (COA) is forging ahead with its COA Patient Advocacy Network (CPAN), says Rose Gerber, director of patient advocacy for COA. The network’s major focuses include increasing its presence and making it easier for community practices to get involved.

July 13th 2017

ICER Draft Report Assesses Value of 3 PARP Inhibitors for Ovarian Cancer

Christina Mattina

A new draft report from the Institute for Clinical and Economic Review (ICER) evaluates the evidence on the effectiveness and value of 3 drugs used to treat ovarian cancer.

July 12th 2017

Novartis' CAR-T Therapy, CTL019, Approved 10-0 by FDA's ODAC

Surabhi Dangi-Garimella, PhD

CTL019 was unanimously approved by FDA’s Oncologic Drugs Advisory Committee (ODAC) for the treatment of children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia.

July 12th 2017

FDA Grants Full Approval, Expands Indications for Blinatumomab in ALL

Christina Mattina

Blinatumomab is now fully approved as a treatment for relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), following FDA assessment of new trial data on survival outcomes and its use in certain clinical subgroups.

July 11th 2017

Novartis' CAR-T Therapy for Pediatric Leukemia to Face FDA Advisory Panel

Alison Rodriguez

Novartis’ chimeric antigen receptor T-cell (CAR-T) therapy for treating pediatric leukemia is on the cusp of being the first FDA-approved gene therapy, which will lead to new developments and utilizations of CAR-T therapy for treating other advanced blood cancers.

July 10th 2017

New Science Paper Questions Sequential Role of Lymph Nodes in CRC Metastases

Surabhi Dangi-Garimella, PhD

A new study, published by researchers at Massachusetts General Hospital, has questioned the traditional model of cancer metastases that implicates lymph nodes in helping seed cancer cells at distant sites.

July 10th 2017

Rural America's High Cancer Mortality Rates Point to Growing Disparities

Christina Mattina

A recent analysis of cancer incidence and mortality rates across America finds that while those in rural counties are less likely to get cancer, cancer-related mortality rates are higher than in more populous areas, and this disparity is increasing over time.

July 10th 2017

Review Discusses Pneumonitis as an Adverse Effect of Checkpoint Inhibitors

Alison Rodriguez

Research published by Cancer Management & Research explores the efficacy of treating multiple malignancies with immune checkpoint inhibitors and programmed cell death-1 inhibitors (PD-1). The review specifically analyzes the presence of pneumonitis as an adverse event following treatment of checkpoint inhibitors.

July 9th 2017

Study Reveals Need for Insurer Transparency, Greater Access for Patients With Cancer

Alison Rodriguez

Narrow insurance coverage has forced some patients to choose between lower premium plans and access to better quality cancer care, according to a recent report.

July 9th 2017

New Antibody Demonstrates 2-Pronged Approach in Treating Blood Cancer

Alison Rodriguez

A study published by BloodAdvances, a Journal of the American Society of Hematology, demonstrated the potential of the 2-pronged approach in treating non-Hodgkin lymphoma, multiple myeloma, and acute myeloid leukemia.

July 8th 2017

RAS Panel for Detecting Genetic CRC Mutations Approved by FDA

Christina Mattina

The FDA has approved the Praxis Extended RAS Panel for genetic testing in patients with metastatic colorectal cancer (CRC). Detecting certain tumor mutations using the test could have important implications for treatment decisions.

July 7th 2017

Dr Barbara McAneny Discusses the Continuing Evolution of the COME HOME Model

As more practices adopt the COME HOME model, they are adapting it to fit their needs, explained Barbara McAneny, MD, chief medical officer of New Mexico Oncology Hematology Consultants. However, some practices may not have the resources to keep up with data collection requirements while ramping up clinical interventions.

July 6th 2017

Phase 3 Trial Results Support Nivolumab Over Ipilimumab for High-Risk Melanoma

Christina Mattina

A phase 3 trial in patients with advanced melanoma found that nivolumab (Opdivo) outperformed ipilimumab (Yervoy) in terms of recurrence-free survival.

July 6th 2017

Chemo-Radiotherapy Increases Survival Rates Among Lung Cancer Patients

Alison Rodriguez

Advanced radiotherapy treatment, combined with chemotherapy, in small cell lung cancer leads to higher survival rates and lower toxicity, according to a new study.

July 5th 2017

Depression Among Cancer Caregivers Can Lead to Health Problems

AJMC Staff

A collaborative research study, based on survey results gathered by the American Cancer Society, has found a correlation between depressive symptoms in cancer caregivers and a decline in their physical health.

July 5th 2017

DigniCap Scalp Cooling System Now Approved for Use in All Solid Tumors

Alison Rodriguez

The FDA has approved expanding the use of the DigniCap Cooling System to prevent chemotherapy-associated alopecia for all patients with solid tumors.

July 5th 2017

Dr Basit Chaudhry on the Impact of the Oncology Care Model

As practices adopt the Oncology Care Model, practices should consider how this change will influence the practice and make efforts to continue engaging with the staff during this process, said Basit Chaudhry, MD, PhD, founder of Tuple Health.

July 4th 2017

Immuno-Oncology Drug, AM0010, Is Effective in Treating Advanced Pancreatic Cancer

Alison Rodriguez

New clinical trial research presented at the European Society for Medical Oncology 19th World Congress on Gastrointestinal Cancer suggests that ARMO BioSciences’ immuno-oncology drug, AM0010, is effective in treating patients with advanced pancreatic cancer.

July 3rd 2017

New Flow Cytometry-Based Test Approved for Certain Leukemias and Lymphomas

Surabhi Dangi-Garimella, PhD

A new liquid biopsy test that uses flow cytometry to detect cancer cells has been FDA approved for chronic leukemia, acute leukemia, non-Hodgkin lymphoma, myeloma, myelodysplastic syndrome, and myeloproliferative neoplasms.

...

68 69 70 71 72 73 74 75 76

...

184 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions